Trade Articles

i

Bioanalysis Zone | November 2022

Bioanalysis Considerations for CAR T-Cell Therapies

i

Drug Discovery and Development | October 2022

Preparing an IND submission: Here is what drug sponsors should anticipate

i

Contract Pharma | October 2022

Comprehensive Bioanalysis of ADCs in DMPK Studies

i

OnDrug Delivery | August 2022

Dissecting the Delicate Delivery Process for Ocular Gene Therapy

i

Bioanalysis Zone | June 2022

Utilizing Monoclonal Antibodies to Regulate Checkpoint Proteins & Boost Immune Response

i

Drug Discovery & Development | February 2022

5 questions drug developers need to ask when vetting laboratory testing partners

i

American Pharmaceutical Review | December 2021

Improving Preclinical Outcomes: De-Risking Your Drug Development Program

i

Contract Pharma | June 2021

Preparing for Preclinical Testing: A Readiness Checklist

i

Drug Discovery & Development | May 2021

Managing critical reagents through drug development

i

AAPS Journal | May 2021

Bioanalysis in the Age of New Drug Modalities

i

Drug Discovery & Development | April 2021

Analyzing FDA guidance on DDI studies for therapeutic proteins

i

Bioanalysis Zone | November 2022

Bioanalytical considerations for gene and cell therapeutic products

i

American Pharmaceutical Review | August 2022

Antibody-Drug Conjugates (ADCs): Potent Cancer Killers with PK Challenges

i

Bioanalysis Zone | August 2022

Examining the dominant bioanalytical methods for Oligo development

i

Drug Discovery & Development | July 2022

Bioanalytical method development and validation using Quanterix’s Simoa platform

i

Pharmaceutical Outsourcing | May 2022

Protein Biomarkers: The Correlation Between Proteins, Health Conditions and Exogenous Products

i

Drug Discovery & Development | December 2021

The opportunities and challenges inherent in using protein biomarkers for new drug development

i

Genetic Engineering and Biotechnology News | November 2021

Using In Vitro–In Vivo Extrapolation to Predict Human Clearance

i

Regulatory Focus | June 2021

The transition to ICH M10 and its impact on global submissions

i

Life Science Leader | May 2021

Improving Submission Quality: Preparing For Regulatory Differences

i

PharmaManufacturing | March 2021

Winning the drug development relay